New York, May 28, 2026, 07:04 (EDT)
NewAmsterdam Pharma Company N.V. shares head into Thursday’s U.S. session with a fresh insider filing in the tape and the stock still priced around the next tests for obicetrapib, its late-stage cholesterol drug. NAMS last traded at $36.56, up about 1.3% from its previous close, with a market value near $4.27 billion.
That move stood out against a quiet broader tape. A Reuters market-data snapshot showed the S&P 500 up 0.02% and the Nasdaq Composite up 0.07%, leaving the company’s shares moving more on its own news flow than on index strength.
The reason this matters now is not one filing alone. NewAmsterdam is between catalysts: the company has said decisions on regulatory approval from the EMA, the UK and Switzerland for obicetrapib and the obicetrapib/ezetimibe fixed-dose combination are expected in the second half of 2026, with possible launches by Menarini in Germany and the UK in the fourth quarter if approvals come through. Chief Executive Michael Davidson said this month that “clinical execution remains strong” and that management was “optimistic about the interim analysis” of PREVAIL, planned for the fourth quarter. NewAmsterdam Pharma
Thursday is a regular Nasdaq trading day after the Memorial Day closure earlier in the week. Nasdaq lists Memorial Day, May 25, as closed on its 2026 holiday schedule, and regular Nasdaq hours run from 9:30 a.m. to 4:00 p.m. Eastern Time.
The May 27 Form 4 — a U.S. filing that reports changes in an insider’s share ownership — showed Chief Accounting Officer Louise Frederika Kooij exercised options for 65,000 ordinary shares on May 26 and sold 65,000 shares at a weighted average price of $35.69. The sale prices ranged from $35.12 to $36.09, and the filing said the transaction was made under a Rule 10b5-1 plan, a pre-arranged trading plan used by insiders.
A separate Form 144, a notice filed before a proposed sale of restricted or control stock, listed 210,000 ordinary shares for Kooij’s account with an aggregate market value of $7.44 million. The notice named J.P. Morgan Securities as broker, Nasdaq as the exchange and Feb. 23 as the trading-plan adoption date.
The transaction also comes after an April filing said NewAmsterdam and Kooij had agreed that her employment as chief accounting officer would end on Aug. 31. The same filing said the separation agreement included a lump-sum payment equal to 12 months of base salary and extended vesting of certain options and restricted stock units through Jan. 10, 2027.
NewAmsterdam still looks like a late-stage biotech story, not an earnings story. Its 10-Q showed $707.3 million in cash, cash equivalents and marketable securities at March 31, while the company posted a first-quarter net loss of $48.4 million, wider than $39.5 million a year earlier.
The company, based in the Netherlands, is developing obicetrapib as an oral, once-daily CETP inhibitor; CETP is a protein involved in cholesterol transfer. NewAmsterdam is aiming it at LDL-C, or low-density lipoprotein cholesterol, often called “bad” cholesterol, in patients whose current therapy has not worked well enough or has not been tolerated. NewAmsterdam Pharma
The competitive field is busy. Amgen’s Repatha is an injectable PCSK9 inhibitor, a class that lowers LDL-C by helping the liver clear LDL from the blood; Novartis’s Leqvio is a twice-yearly siRNA injection; and Merck says enlicitide has the potential to become the first approved oral PCSK9 inhibitor. That puts NewAmsterdam’s oral pitch in a crowded, but large, cholesterol-treatment race.
But the downside is plain. PREVAIL may not stop early for efficacy, regulatory decisions could slip or go against the company, and NewAmsterdam has not yet turned obicetrapib into product sales. Its quarterly filing says significant additional research, development and regulatory approval will be required before commercialization, and that it is uncertain when, if ever, the company will realize significant revenue from product sales.
For now, the stock’s reference points are narrow: the latest insider filings, the cash runway, and whether obicetrapib can clear the next clinical and regulatory gates without losing momentum.
